IMMIX BIOPHARMA, INC. — Net Income by Fiscal Year
6 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/92a40479-cee7-41d4-9d4f-dce8b9e6c936/serie/net-income
| Fiscal year | Net Income | Period | Evidence |
|---|---|---|---|
| FY 2025 | $-29.4M | 2025-01-01 – 2025-12-31 | evidence 0001493152-26-021764 |
| FY 2024 | $-21.6M | 2024-01-01 – 2024-12-31 | evidence 0001641172-25-000387 |
| FY 2023 | $-15.4M | 2023-01-01 – 2023-12-31 | evidence 0001493152-24-011975 |
| FY 2022 | $-8.2M | 2022-01-01 – 2022-12-31 | evidence 0001493152-24-011975 |
| FY 2021 | $-24.4M | 2021-01-01 – 2021-12-31 | evidence 0001493152-22-007921 |
| FY 2020 | $-1.1M | 2020-01-01 – 2020-12-31 | evidence 0001493152-22-007921 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).